Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | TERT | O14746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL29430498 | 0.90 | CA2 (0.39) | CA2CA9 | |
| SCHEMBL28901062 | 0.80 | CA2 (0.50) | CA2CA9 | |
| SCHEMBL32665835 | 0.79 | CA2 (0.39) | CA2CA9 | |
| SCHEMBL31413665 | 0.78 | CA2 (0.38) | CA2CA9 | |
| SCHEMBL20829940 | 0.77 | CA2 (0.48) | CA2CA9 | |
| SCHEMBL22688016 | 0.76 | TDP1 (0.38) | CA2CA9 | |
| SCHEMBL28099596 | 0.76 | CA2 (0.47) | CA2CA9 | |
| SCHEMBL23568449 | 0.75 | CA2 (0.36) | CA2CA9 | |
| SCHEMBL15057676 | 0.75 | PAOX (0.47) | CA2CA9 | |
| SCHEMBL21981211 | 0.74 | CA2 (0.48) | CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409734-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-12-29 | — | — | US | disclosed |
| EP-3965891-A1 | ANTIBODY DRUG CONJUGATES | Takeda Pharmaceutical Company Limited (JP) | 2022-03-16 | — | — | EP | disclosed |
| CN-114173824-A | Antibody drug conjugates | 武田药品工业株式会社 | 2022-03-11 | — | — | CN | disclosed |
| WO-2020229982-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409734-A1 | ANTIBODY DRUG CONJUGATES | STING1, CGAS, TBK1 | CA2 4448/4885CA9 3642/4885TERT 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.